万拉法新与西酞普兰治疗抑郁症对照研究.docVIP

万拉法新与西酞普兰治疗抑郁症对照研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：万拉法新与西酞普兰治疗抑郁症对照研究 1 1 对象与方法 2 2 结果 3 3 讨论 4 文2：万拉法新与氟西汀治疗抑郁症对照研究 5 1 对象与方法 6 2 结果 6 参考文摘引言： 8 原创性声明（模板） 9 文章致谢（模板） 10 正文 万拉法新与西酞普兰治疗抑郁症对照研究 文1：万拉法新与西酞普兰治疗抑郁症对照研究 A control study on venlafaxine vs. citaloparm in the treatment of depression 【Abstract】 Objective To evaluate the clinical curative effects and safety of venlafaxine vs. citaloparm in the treatment of depression. Methods 65 patients with depressive disorder were randomly divided into venlafaxine(n=32) and citaloparm(n=33) group for 6 weeks. The curative effects were assessed with the Hamilton Depression Scale (HAMD) and advee effects with the Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of the 1st, 2nd and 6th week, respectively. Results Excellence rates were respectively % in venlafaxine and % in the citaloparm group, which showed no significant difference(P); at the end of the 1st week, score of the HAMD was significantly lower in the venlafaxine than in the citaloparm group(P). There were no significant differences at the ends of the 2nd, 4th and 6th week between the 2 groups(P); incidences of advee effects were respectively % in the venlafaxine and % in the citaloparm group, difference was not significant(P). Conclusion Venlafaxine has therapeutic equivalence to citaloparm in depression, but takes effects faster. 【Keywords】 Venlafaxine; citaloparm; depression; the HAMD; the TESS 有 文献 表明［1］，30%的抑郁症患者对各种治疗没有反应，40%～45%的慢性抑郁症患者缺乏治疗反应。且在临床治疗过程中发现，不同的药物有着不尽相同的副作用。为此作者采用万拉法新（商品名：怡诺思）与西酞普兰（商品名：喜普妙）进行了对照研究，以探讨万拉法新的临床疗效及安全性，现报告如下。 1 对象与方法 对象 选取2005年5月～2006年5月在我院门诊及住院治疗的65例抑郁症患者为研究对象。入组标准：（1）符合《 中国 精神障碍分类与诊断标准》第3版（CCMD3）抑郁症诊断标准；（2）年龄24 a～81 a；（3）汉密顿抑郁量表（HAMD）评分≥18分；（4）入组1 w前未服用任何抗精神病及抗抑郁药物；（5）排除躯体及脑器质性疾病、双相障碍快速循环型、精神分裂症及妊娠、哺乳期妇女；（6）无酒精或其它活性物质滥用史。将入组病例随机分为万拉发新组和西酞普兰组。万拉法新组32例，男13例，女19例，平均年龄（±） a，平均病程（±） mo。西酞普兰组33例，男15例，女18例，平均年龄（±） a，平均病程（±） mo。两组平均年龄、病程差异无显著性（P＞）。万拉法新组因血压升高而脱落1例，实际完成治疗31例；西酞普兰组因头昏